From FDA Approves First Drug for Exelixis of South San Francisco:

Exelixis Logo—

Exelixis (NASDAQ: EXEL) is a South San Francisco biotechnology company developing drugs for thyroid cancer, prostate cancer, and other conditions.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Sponsored · Whitepaper
How to Approach Life Sciences Fundraising
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Xconomy on Demand

We offer a number of ways to subscribe for free!